Latest Product Innovation News

Insignia Financial’s Funds Under Management and Administration edged up to $342 billion, driven by strong inflows into its Wrap platform and multi-asset solutions, while Master Trust funds faced ongoing outflows amid product transitions.

Adveritas Limited has reported a record $14.25 million annualised recurring revenue for the December 2025 quarter, driven by strong US market growth and AI-enhanced product development. The company’s strategic focus on media agency partnerships and new product lines signals robust momentum ahead.

Wellnex Life reports a $2.4 million EBITDA improvement in H1 FY26 and reaches breakeven by Q2, supported by strong Pain Away sales and expanded distribution.

Australian Ethical reported a slight 1% decline in funds under management to $14.08 billion for December 2025, balancing positive retail flows against institutional mandate losses and market headwinds.

Aquirian Limited reports a robust first half of FY26 with revenue up 27.4% and EBITDA more than doubling, driven by strategic facility upgrades and promising joint ventures.

ECS Botanics reports a $218k positive operating cash flow in Q2 FY26, driven by strong B2C growth and new product launches. The company also secured $1.95 million in funding to fuel European expansion and product development.

Acusensus Limited has announced a $30 million equity placement to bolster its balance sheet, alongside winning a landmark $34 million contract in Connecticut, marking a significant step in its US expansion. The company also reported multiple contract expansions in Australia and a new debt facility to support its growth ambitions.

Acusensus Limited has successfully raised $30 million through a placement of 20 million shares at $1.50 each, supported by both existing and new investors. The capital injection aims to fuel business development, product innovation, and operational expansion.

Alexium International has acquired Microtek Laboratories’ microencapsulation and phase-change material business, backed by a $6.8 million entitlement offer to strengthen its manufacturing and innovation capabilities in the US.

Biome Australia has initiated its first human clinical trial for the proprietary probiotic strain Lactobacillus plantarum BMB18, aiming to validate its benefits for digestive and mood-related symptoms.

Myer Holdings Limited reported steady FY25 financial results with $4.076 billion in sales and outlined ambitious growth strategies at its Annual General Meeting, alongside key director re-elections and executive incentives.

Spenda Limited has successfully raised $1.4 million through a private placement, attracting both new and existing sophisticated investors to support its product development and working capital needs.